NCT02035384 - Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 5, 2014

Primary Completion Date

January 15, 2020

Study Completion Date

January 15, 2020

Conditions

Congenital Bleeding DisorderHaemophilia A

Interventions

DRUG

turoctocog alfa

Patients will be treated with commercially available turoctocog alfa as prescribed by the treating physician in clinical daily practice and preferably according to the label for turoctocog alfa in the respective countries.

Trial Locations (41)

1000

Novo Nordisk Investigational Site, Ljubljana

4020

Novo Nordisk Investigational Site, Linz

4032

Novo Nordisk Investigational Site, Debrecen

7700

Novo Nordisk Investigational Site, Mohács

8036

Novo Nordisk Investigational Site, Graz

8091

Novo Nordisk Investigational Site, Zurich

28203

Novo Nordisk Investigational Site, Charlotte

31033

Novo Nordisk Investigational Site, Castelfranco Veneto

33076

Novo Nordisk Investigational Site, Bordeaux

35033

Novo Nordisk Investigational Site, Rennes

35128

Novo Nordisk Investigational Site, Padua

35392

Novo Nordisk Investigational Site, Giessen

36604

Novo Nordisk Investigational Site, Mobile

38118

Novo Nordisk Investigational Site, Braunschweig

42055

Novo Nordisk Investigational Site, Saint-Etienne

47051

Novo Nordisk Investigational Site, Duisburg

48143

Novo Nordisk Investigational Site, Münster

50134

Novo Nordisk Investigational Site, Florence

60596

Novo Nordisk Investigational Site, Frankfurt am Main

61615

Novo Nordisk Investigational Site, Peoria

64546

Novo Nordisk Investigational Site, Mörfelden-Walldorf

67098

Novo Nordisk Investigational Site, Strasbourg

80331

Novo Nordisk Investigational Site, München

84113

Novo Nordisk Investigational Site, Salt Lake City

87106

Novo Nordisk Investigational Site, Albuquerque

90127

Novo Nordisk Investigational Site, Palermo

95123

Novo Nordisk Investigational Site, Catania

95160

Novo Nordisk Investigational Site, Montmorency

90502-2004

Novo Nordisk Investigational Site, Torrance

625 00

Novo Nordisk Investigational Site, Brno

04289

Novo Nordisk Investigational Site, Leipzig

GR-11527

Novo Nordisk Investigational Site, Athens

H-1134

Novo Nordisk Investigational Site, Budapest

2545AA

Novo Nordisk Investigational Site, The Hague

3584 CX

Novo Nordisk Investigational Site, Utrecht

02-091

Novo Nordisk Investigational Site, Warsaw

975 17

Novo Nordisk Investigational Site, Banská Bystrica

04001

Novo Nordisk Investigational Site, Košice

08035

Novo Nordisk Investigational Site, Barcelona

205 02

Novo Nordisk Investigational Site, Malmo

171 76

Novo Nordisk Investigational Site, Stockholm